SVB Leerink Equities Analysts Reduce Earnings Estimates for Innate Pharma S.A. (NASDAQ:IPHA)

Share on StockTwits

Innate Pharma S.A. (NASDAQ:IPHA) – Research analysts at SVB Leerink dropped their FY2025 earnings estimates for shares of Innate Pharma in a research report issued on Tuesday, April 6th. SVB Leerink analyst D. Graybosch now anticipates that the company will post earnings of $0.26 per share for the year, down from their prior estimate of $0.30. SVB Leerink currently has a “Market Perform” rating and a $7.00 target price on the stock.

Several other equities analysts have also weighed in on IPHA. Zacks Investment Research raised shares of Innate Pharma from a “sell” rating to a “hold” rating in a research report on Tuesday, February 2nd. HC Wainwright reissued a “buy” rating and issued a $13.00 price objective on shares of Innate Pharma in a research report on Thursday, February 4th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $7.94.

Shares of IPHA stock opened at $4.23 on Thursday. The stock has a market cap of $334.13 million and a P/E ratio of -12.44. The company has a fifty day moving average price of $4.44 and a two-hundred day moving average price of $4.43. Innate Pharma has a one year low of $3.55 and a one year high of $8.23.

About Innate Pharma

Innate Pharma SA, a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma.

See Also: Can individual investors take part in an IPO?

Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with's FREE daily email newsletter.